NovaBridge ragistomig Phase 1 data presented at ESMO

Q: What clinical update did NBP report about ragistomig?

NBP reported that clinical data from the ongoing Phase 1 clinical trial of ragistomig were presented in a dose-optimization poster by ABL Bio at the ESMO Congress 2026 in Madrid on October 23, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

NovaBridge Biosciences (NBP) reported that clinical data from the ongoing Phase 1 clinical trial of ragistomig, also known as ABL503 or TJ-L14B, were presented by ABL Bio in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on October 23, 2026. The poster concerned dose optimization; ragistomig is a bispecific antibody targeting PD-L1 and 4-1BB that NovaBridge and ABL Bio are jointly developing.

Filing Explained

The ragistomig information in this October 23, 2026 6-K is incorporated into NovaBridge’s listed F-3 and S-8 registration statements, including related prospectuses, from the date furnished, unless later filed or furnished documents supersede it.

Key Terms

Phase 1 clinical trial, bispecific antibody, PD-L1, 4-1BB

4 terms

Phase 1 clinical trial medical

"ongoing Phase 1 clinical trial of ragistomig"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

bispecific antibody medical

"a bispecific antibody targeting both PD-L1 and 4-1BB"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

PD-L1 medical

"targeting both PD-L1 and 4-1BB"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

4-1BB medical

"targeting both PD-L1 and 4-1BB"

4-1BB is a protein on certain white blood cells that acts like an accelerator pedal, boosting the activity, survival and memory of immune cells when they encounter disease. It matters to investors because drugs that stimulate or dampen 4-1BB can dramatically change treatment effectiveness for cancers and immune disorders; clinical trial outcomes, safety signals and regulatory decisions around such therapies can therefore swing a biotech company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clinical update did NBP report about ragistomig?

NBP reported that clinical data from the ongoing Phase 1 clinical trial of ragistomig were presented in a dose-optimization poster by ABL Bio at the ESMO Congress 2026 in Madrid on October 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/23/2026 - 09:15 AM EDT Accepted by SEC EDGAR 10/23/2026 - 09:15 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-39173

NovaBridge Biosciences

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

NovaBridge Biosciences (the “Company”) reports that clinical data from the ongoing Phase 1 clinical trial of ragistomig (also known as “ABL503” or “TJ-L14B”), a bispecific antibody targeting both PD-L1 and 4-1BB being jointly developed by the Company and ABL Bio Inc. (“ABL Bio”), were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 by ABL Bio in Madrid, Spain, on October 23, 2026.

Incorporation by Reference

The information set forth in this report on Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684, File No. 333-279842, File No. 333-290195 and File No. 333-298369) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX


Exhibit No.	Description

99.1	Poster – Dose Optimization of Ragistomig (ABL503/TJ-L14B), a PD-L1x 4-1BBBispecific Antibody

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.